The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

Accelerated repopulation is a main reason for locoregional failure after fractionated radiotherapy for head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor receptor (EGFR) is a key ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...

“We postulate that these observations may provide novel opportunities for therapeutic interventions for EGFR driven cancers.” “We postulate that BUB1 helps in the formation and stabilization of EGFR ...

Dr Mark Kris examines new OS results for chemo plus osimertinib in EGFR-mutant NSCLC and how they align with survival gains seen previously with other EGFR TKIs.

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...